Introduction {#s001}
============

Gemcitabine as a single agent or in combination therapy is a mainstay treatment for pancreatic adenocarcinoma.^[@B1],[@B2]^ Gemcitabine is generally well tolerated, with a favorable toxicity profile.^[@B1]^ There are case reports of gemcitabine-associated digital ischemia (DI), but there are only two prior case reports in the treatment of pancreatic adenocarcinoma.^[@B3]^ Here we present a case of gemcitabine-associated DI in a patient with pancreatic adenocarcinoma, along with a literature review.

Case Report {#s002}
===========

A 70-year-old female with metastatic pancreatic adenocarcinoma receiving gemcitabine and nab-paclitaxel presented to clinic with numbness and tingling in her bilateral hands. Owing to initial concern for nab-paclitaxel-associated neurotoxicity, nab-paclitaxel was discontinued while the patient was continued on gemcitabine (cumulative dose 4160 mg/m^2^). At 2-week follow-up, the patient reported progressive tenderness, coolness, and purple discoloration of her bilateral index fingers that was initially relieved with warm water immersion. Gemcitabine was promptly discontinued and the patient was admitted for further management. The patient had previously received FOLFOX and then FOLFIRI. She had a history of soleal deep vein thrombosis but no history of rheumatological, connective tissue or peripheral vascular disease. She was a 15-pack/year smoker but quit 2 years previously. Her medications included diltiazem, pravastatin, and aspirin.

Upon admission, the patient\'s vital signs were within normal limits. Examination revealed bilateral necrotic index fingers ([Fig. 1](#f1){ref-type="fig"}). Basic laboratories revealed leukocytosis, mild anemia, and hypoalbuminemia. The prothrombin time/international normalized ratio, partial thromboplastin time, lupus anticoagulant, anticardiolipin antibody, cryoglobulin S, C3/C4, and extractable nuclear antigen testing were unremarkable. Antinuclear antibody was positive with 1:320 titer and speckled pattern. Echocardiogram showed no evidence of intracardiac thrombi. CT angiography revealed no evidence of systemic emboli. Arterial Doppler studies showed immeasurable digit/arm indices ([Fig. 2](#f2){ref-type="fig"}). Given the negative evaluation for competing etiologies, gemcitabine-associated DI was diagnosed. The patient was managed with gemcitabine discontinuation, along with initiation of calcium-channel blockade, nitrates, and opiates. Therapeutic enoxaparin was also initiated, but was subsequently discontinued because of gastrointestinal bleed. Despite treatment, the patient\'s symptoms progressed to dry gangrene of the bilateral index fingers.

![Images of fingers/hands. Red arrows, bilateral index fingers demonstrating cyanosis, digital ischemia, and necrosis. Box, remaining digits demonstrating cyanosis and distal erythema.](fig-1){#f1}

![Digit-arm indices. Digit-arm arterial Doppler tracings and indices demonstrating loss of arterial flow to the bilateral index fingers (second digit).](fig-2){#f2}

Discussion {#s003}
==========

Gemcitabine has been associated with thrombotic vascular complications affecting various organ systems.^[@B3]^ However, DI is a rare adverse effect of gemcitabine likely caused by drug-related microvascular endothelial damage and a relative hypercoagulable state,^[@B3]^ with only case reports to aid clinicians in identifying risk factors, recognizing signs/symptoms, and guiding management decisions. A PubMed search using "digital ischemia/necrosis" and "gemcitabine," selecting English language articles and also using relevant cases from those articles\' references revealed nine cases of gemcitabine-associated DI ([Table 1](#T1){ref-type="table"}), with only two cases occurring in pancreatic adenocarcinoma. Risk factors included tobacco use, diabetes, peripheral vascular disease, systemic sclerosis, combination chemotherapy, and cumulative gemcitabine dose \>10,000 mg/m.^[@B2],[@B4]^ Two cases reported favorable outcomes. Kuhar et al. reported using infusion of a prostacycline analogue, NSAIDs, and opioids.^[@B4]^ Vénat-Bouvet et al. reported intravenous prostaglandin-E2 analogue alone.^[@B12]^ In each case, gemcitabine was withdrawn.

###### 

**Reported Cases of Gemcitabine-Associated Digital Ischemia**

  Case                          Age (y/o)   Sex   Malignancy   Risk factors                                              Chemotherapy regimen (cumulative dose)                Affected area                                               Treatment for digital ischemia                                                                                                                                Outcome
  ----------------------------- ----------- ----- ------------ --------------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------
  So et al. (this article)      70          F     Pancreatic   Former tobacco                                            Gemcitabine (4160 mg/m^2^)                            Bilateral second digits                                     Stopped gemcitabine, started calcium-channel blockade, nitrates, opiates, and enoxaparin                                                                      Progressed to dry gangrene of the bilateral second digits
  Kuhar et al.^[@B4]^           65          M     Pancreatic   Renal impairment                                          Gemcitabine (4000 mg/m^2^)                            All digits of both hands                                    Stopped gemcitabine, started prolonged infusion of a prostacycline analogue, NSAIDs, and opioids                                                              Symptoms resolved in all digits except one, which required amputation
  Kuhar et al.^[@B4]^           77          M     Bladder      Tobacco, thrombocytosis and peripheral vascular disease   Gemcitabine (4000 mg/m^2^) Cisplatin                  Two digits of a right foot                                  Stopped gemcitabine, started prolonged infusion of a prostacycline analogue, percutaneous luminal angioplasty of right superficial femoralis artery           Complete resolution
  Zaima et al.^[@B5]^           69          M     Pancreatic   Systemic sclerosis, tobacco, and diabetes                 Gemcitabine (7600 mg/m^2^)                            Multiple fingers and toes                                   Stopped gemcitabine, started prostaglandins, vasodilators, antiplatelet drugs, antithrombin, bosentan hydrate, and systemic nerve block                       Fixed gangrene not requiring amputation of affected digits
  Holstein et al.^[@B6]^        70          F     Urothelial   none                                                      Gemcitabine (3000 mg/m^2^) Cisplatin or carboplatin   Left fourth, fifth digits and right third, fourth digits    Stopped gemcitabine, started bilateral brachial plexus blockade, intravenous prostacyclin analogue, fractionated heparin, oral corticosteroids, and aspirin   Partial clinical improvement, but with residual fixed gangrene
  Vénat-Bouvet et al.^[@B7]^    61          M     Urothelial   Tobacco                                                   Gemcitabine (10,000 mg/m^2^) Cisplatin                Second, third digits of bilateral hands                     Stopped gemcitabine, started intravenous prostaglandin-E2 analogue                                                                                            Complete resolution
  Clowse and Wigley^[@B8]^      50          F     Lung         Systemic sclerosis                                        Gemcitabine (unspecified dose) Carboplatin            Right second, fourth, fifth fingers and left third finger   Started calcium channel blocker, prednisolone, cephalexin, gabapentin, and two stellate ganglion blocks                                                       Fixed gangrene requiring amputation of affected digits
  Staff et al.^[@B9]^           57          F     Ovarian      Hypercholes-terolemia and carpal tunnel syndrome          Gemcitabine (unspecified dose) Carboplatin            Left second, third, and fourth digits                       Started aspirin, calcium channel blocker, low-molecular weight heparin                                                                                        Partial clinical improvement NOS
  Yildiz et al.^[@B10]^         59          M     Lung         Tobacco                                                   Gemcitabine (5000 mg/m^2^)                            Digits of both hands                                        Stopped gemcitabine, started vasodilator agents, low-molecular weight heparin and aspirin                                                                     Partial clinical improvement, NOS
  Banach and Williams^[@B11]^   59          M     Lung         Diabetes                                                  Gemcitabine (unspecified dose)                        Right fourth digit, and left first, second digits           Stopped gemcitabine, started intermittent corticosteroids                                                                                                     Fixed gangrene

NOS, not otherwise specified; NSAID, non-steroidal anti-inflammatory drugs.

In this case, there was no underlying disease. Prior smoking was the only risk factor. The cumulative gemcitabine dose of 4160 mg/m^2^ was lower than previous reports. Given the lack of risk factors and initial suspicion for competing etiologies, gemcitabine was not immediately discontinued. Despite eventual discontinuation of gemcitabine and initiation of vasodilator therapy, the patient suffered irreversible digital necrosis. Therefore, based on variability in risk factors and cumulative dose exposure, clinicians should maintain a high degree of suspicion for gemcitabine-associated DI.

Conclusion {#s004}
==========

DI is a rare side effect of gemcitabine, which may be attributable to endothelial damage and a hypercoagulable state. There is variability in risk factors, presenting signs/symptoms, and treatment response, creating a diagnostic and treatment dilemma for clinicians. Withdrawing gemcitabine and initiation of prostaglandins and/or alternative vasodilators may be an effective treatment modality.
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